Local biotech invests in erectile dysfunction drug

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

The company – which specializes in repurposing drugs already approved for other purposes – has signed a letter of intent to license a sublingual formation for drugs used to treat erectile dysfunction. Sublingual formations (which allow drugs to be dissolved under the tongue) absorb more quickly and therefore take effect sooner.

"We expect to move this product through pivotal trials and through regulatory approval over the next year and intend to begin marketing within two years," said Pacific Therapeutics CEO Douglas Unwin.

"We expect to complete the license in the first quarter of 2013, and move rapidly to the late-stage clinical trials and marketing."

In 2006, the market for drugs for treating erectile dysfunction exceeded $3 billion, the company said.

Pacific Therapeutics has two other drugs in the pipeline, both of which are for the treatment of scarring of human tissue.

Its lead product, PTL-202, is a combination of drugs being tested for efficacy in treating idiopathic pulmonary fibrosis, a progressive scarring of the lungs. The drug is already approved by the Food and Drug Administration in the U.S. and is currently in stage one of clinical trials.

nbennett@biv.com

@nbennett_biv

comments powered by Disqus

Also Read

More From Innovation

Students in elementary school today were all born at a time when having the Internet in one’s home was a given.  

Read Article

Straighten up. It may help your company save money.

Read Article

Innovation

Engaging with big data

By Oct. 14, 2014, 9:37 a.m.

Big data changes the way we live, think and do business

Read Article

While one B.C. early-stage company debuts its electric bus, other local businesses, including Vancouver’s Westport Innovations, have struggled to make a profit in the sector 

Read Article

LinkedIn’s pay-per-click program is unique because it allows you to advertise to selected types of individuals or businesses based on criteria such as company size, ...

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

×